Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.112SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-7333.08China
B.1.258.23SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-7333.08China
XFSChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-7333.08China
AY.39.3 (Delta)SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-7333.08China
B.1.258.17SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-7333.08China
B.51SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-7333.08China
BQ.1.1.56ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-7434.86France
BA.2.3.2ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-7459.53Germany
BA.2.61ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-7459.53Germany
BM.3ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-7459.53Germany
BS.1ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-7459.53Germany
BF.36ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-7459.53Germany
BC.1ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-7459.53Germany
EG.2.4ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-7537.46Japan
B.19EWon-ETTCGGAAGAGACAGGTACGTT2147.622625926279F-7551.2South Korea
CP.8ORF1abWon-ORF1abCATGTGTGGCGGTTCACTAT20501544115460F-7924.15South Korea
B.50ORF1abPasteur-ORF1ab-2GGTAACTGGTATGATTTCG1942.111408014098F-7941.22France
B.1.1.515NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
B.1.287NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
B.1.112NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
BA.1.17.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
AY.4.16 (Delta)NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
B.1.177.71NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
B.1.1.445NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
B.1.1.516NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
XBF.7.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
HK.18NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
FL.39.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
BA.4.6.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
XLNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
XBB.1.14NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
B.11NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
DV.7.1.4NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
EG.11NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
XCZNUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
FL.20NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
FL.13.3NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-7949.56US
XBB.1.38.1EHuang-EGCAGCAGTACGCACACAATC20552637626357R-8009.2China
AY.127.1 (Delta)ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-8301.01China
XBB.2.3.19ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-8369.06China
JB.1.1ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-8369.06China
B.1.1.98SYoung-STATACATGTCTCTGGGACCA20452176321782F-8411.27Singapore
BQ.1.1.76ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-8429.46France
XBB.1.5.91ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-8429.46France
BW.1.2ORF1abNIID WH-1 Seq F519R840GACATAGCGAGTGTATGCC1952.63823805R-8500.25Japan
B.1.112ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-8520.83France
BF.7.14.5ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-8567China
XBB.1.11.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-8626.22Germany
BA.5.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-8626.22Germany
DJ.1.1.1ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-8626.55Germany
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used